Loren W. Wass - 14 Oct 2021 Form 4 Insider Report for Bionik Laboratories Corp.

Role
Chief Commercialization Officer
Signature
/s/ Loren Wass
Issuer symbol
BNKL on OTC
Transactions as of
14 Oct 2021
Net transactions value
$0
Form type
4
Filing time
18 Oct 2021, 17:01:15 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNKL Employee Stock Option (right to buy) Award $0 +55,000 $0.000000 55,000 14 Oct 2021 Common Stock, par value $0.001 55,000 $2.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest as follows: 13,750 on the date of grant and on each of October 14, 2022, October 14, 2023 and October 14, 2024.

Remarks:

Chief Commercialization Officer